Ready-to-Use Boruzu (Bortezomib) from Amneal and Shilpa Approved by FDA

Amneal Pharmaceuticals and Shilpa Medicare have announced US Food and Drug Administration (FDA) approval of Boruzu, a ready-to-use formulation of bortezomib for subcutaneous or intravenous (IV) administration.

Boruzu, a proteasome inhibitor, offers a more efficient approach to treating multiple myeloma and mantle cell lymphoma by eliminating the reconstitution process required for Velcade, the current branded version of bortezomib. This ready-to-use option significantly cuts down on preparation time, enhancing efficiency for healthcare providers.